The UK's second-biggest drug maker is licensing seven established anesthetic medicines to Aspen Global Incorporate (AGI),those beingDiprivan for general anesthesia, topical anesthetic EMLA and five local anesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest; see table below for full details).
Under the deal, announced June 9, AGI acquires commercialization rights outside the US to AstraZeneca’s portfolio of anesthetic medicines for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
